Topic Search: PubMed
.gif) |
J Clin Oncol. 2008 Nov: Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. http://www.ncbi.nlm.nih.gov/pubmed/18854568
CONCLUSION:
Consolidation of first remission with (90)Y-ibritumomab tiuxetan in advanced-stage follicular lymphoma is highly effective with no unexpected toxicities, prolonging PFS by 2 years and resulting in high PR-to-CR conversion rates regardless of type of first-line induction treatment.
|
|
Ann Oncol. 2012 Feb: A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma http://annonc.oxfordjournals.org/content/23/2/415.short
Results: All the 55 patients received four induction cycles with an overall response rate of 96% (38 complete responses [CR] and 15 PR). Fifty-one patients (38 in CR and 13 in PR) received 90Y-IT. By the end of the treatment, 49/55 patients achieved a CR. With a median follow-up of 21 months, the estimated 3-year PFS was 81% and the 3-year OS 100%.
Conclusions: This study has established feasibility, tolerability, and efficacy of a regimen composed by short FMR induction with 90Y-IT consolidation in untreated intermediate/high-risk follicular NHL patients.
|
|
